Anti-neoplastic agent thymoquinone induces degradation of α and β tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts Mahmoud AlhosinAbdulkhaleg IbrahimValérie B. Schini-Kerth PRECLINICAL STUDIES 01 September 2011 Pages: 1813 - 1819
A synthetic decursin analog with increased in vivo stability suppresses androgen receptor signaling in vitro and in vivo Yong ZhangAhmad Ali ShaikCheng Jiang PRECLINICAL STUDIES 26 August 2011 Pages: 1820 - 1829
The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells Pablo E. MorandeSamanta R. ZanettiMirta Giordano PRECLINICAL STUDIES 02 September 2011 Pages: 1830 - 1840
Cluvenone induces apoptosis via a direct target in mitochondria: a possible mechanism to circumvent chemo-resistance? Gianni GuizzuntiEmmanuel A. TheodorakisAyse Batova PRECLINICAL STUDIES 07 September 2011 Pages: 1841 - 1848
The effect of a novel frizzled 8-related antiproliferative factor on in vitro carcinoma and melanoma cell proliferation and invasion Kristopher R. KochChen-Ou ZhangSusan Keay PRECLINICAL STUDIES 20 September 2011 Pages: 1849 - 1864
Identification of a novel class of anti-inflammatory compounds with anti-tumor activity in colorectal and lung cancers Hui-Hua ChangZuohe SongEmmanuelle J. Meuillet PRECLINICAL STUDIES 20 September 2011 Pages: 1865 - 1877
Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors Yoshihiko FujitaRafiqul IslamKazuto Nishio PRECLINICAL STUDIES 13 September 2011 Pages: 1878 - 1886
A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells Ji Hye ParkMee Young AhnHyung Sik Kim PRECLINICAL STUDIES 08 October 2011 Pages: 1887 - 1898
ZJU-6, a novel derivative of Erianin, shows potent anti-tubulin polymerisation and anti-angiogenic activities Frankie LamTracey D. BradshawShudong Wang PRECLINICAL STUDIES 14 October 2011 Pages: 1899 - 1907
Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126 Auke D. AdemaKees SmidGodefridus J. Peters PRECLINICAL STUDIES Open access 15 October 2011 Pages: 1908 - 1916
The nucleoside antagonist cordycepin causes DNA double strand breaks in breast cancer cells Hong Jue LeePetra BurgerAnsgar Brüning PRECLINICAL STUDIES 22 July 2012 Pages: 1917 - 1925
Eribulin mesylate in patients with refractory cancers: a Phase I study Toru MukoharaShunji NagaiHironobu Minami PHASE I STUDIES Open access 02 September 2011 Pages: 1926 - 1933
Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors Alan H. BryceRavi RaoPaul Haluska PHASE I STUDIES 01 September 2011 Pages: 1934 - 1941
Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies Lia GoreE. RiveraS. G. Eckhardt PHASE I STUDIES 20 September 2011 Pages: 1942 - 1949
Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors Sachi MoritaSatoshi OizumiYuichi Ando PHASE I STUDIES 01 October 2011 Pages: 1950 - 1957
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors Andrea Wang-GillamWilliam P. TewAlbert Craig Lockhart PHASE I STUDIES Open access 15 October 2011 Pages: 1958 - 1961
Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours Tanja TrarbachBeate SchultheisJoachim Drevs PHASE I STUDIES 12 October 2011 Pages: 1962 - 1971
A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer In Hae ParkKeun Seok LeeJungsil Ro PHASE I STUDIES 18 October 2011 Pages: 1972 - 1977
Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study Gerardo RosatiStefano CordioRoberto Bordonaro PHASE II STUDIES 19 July 2011 Pages: 1978 - 1983
Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum Jae-Lyun LeeJin-Hee AhnHanjong Ahn PHASE II STUDIES 20 October 2011 Pages: 1984 - 1990
Saturable absorption of sorafenib in patients with solid tumors: a population model Marilyne HorneckerBenoit BlanchetMichel Tod PHASE II STUDIES 18 October 2011 Pages: 1991 - 2000
Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors Thomas J. SemradCourtney EddingsPrimo N. Lara Jr PHASE II STUDIES 21 October 2011 Pages: 2001 - 2007
Nilotinib in patients with metastatic melanoma harboring KIT gene aberration Jin Hyun ChoKyoung Mee KimJeeyun Lee PHASE II STUDIES 09 November 2011 Pages: 2008 - 2014
A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma Takuji OkusakaHiroshi KasugaiKenji Sakata PHASE II STUDIES Open access 21 December 2011 Pages: 2015 - 2025
A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer Natsuko T. OkitaTaito EsakiKen Kato PHASE II STUDIES 10 December 2011 Pages: 2026 - 2031
First case of posterior reversible encephalopathy syndrome associated with vinflunine Carole HelisseyCyrus ChargariSylvestre Le Moulec SHORT REPORT 05 July 2011 Pages: 2032 - 2034
Therapeutic reactivation of mutant p53 protein by quinazoline derivatives Hamish S. SutherlandIn Young HwangBruce C. Baguley SHORT REPORT 13 September 2011 Pages: 2035 - 2045
Sorafenib exposure decreases over time in patients with hepatocellular carcinoma Jennifer ArrondeauOlivier MirFrançois Goldwasser SHORT REPORT 29 October 2011 Pages: 2046 - 2049
Continuing pursuit for ideal systemic anticancer radiotherapeutics Marlein Miranda ConaHuaijun WangYicheng Ni REVIEW 18 October 2011 Pages: 2050 - 2065
Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities Roger B. CohenStéphane Oudard REVIEW Open access 12 February 2012 Pages: 2066 - 2079
Potential mucolytic agents for mucinous ascites from pseudomyxoma peritonei Krishna PillaiJaved AkhterDavid L. Morris REVIEW 23 February 2012 Pages: 2080 - 2086